Genesee Capital Advisors’s PetMed Express PETS Stock Holding History

Genesee Capital Advisors’s Portfolio PETS Stock Details PETS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-22,500	Closed	-$801K	–	79
2020 Q2	$801K	Sell	22,500 -2,522	-10%	-$87.6K	0.74%	46
2020 Q1	$720K	Buy	+25,022	New	+$656K	0.69%	50

Other funds holding PETS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $67.5B AUM 28.09% 1-Year Est. Return

OCMI

Oaktop Capital Management II Chatham, New Jersey $1.34B AUM 114.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Genesee Capital Advisors's PETS Position: Q3 2020 in Review

Genesee Capital Advisors sold out of PetMed Express (PETS) in Q3 2020, closing a stake of 22,500 shares — an estimated $801K sold.

Genesee Capital Advisors first reported a position in PETS in Q1 2020 and held it in 2 quarters. The position peaked at $801K in Q2 2020. 201 funds tracked by Wall St. Rank hold PETS as of Q3 2020.

Genesee Capital Advisors reported no remaining PetMed Express position as of Q3 2020 after selling out during the quarter.
Genesee Capital Advisors sold 22,500 PetMed Express shares in Q3 2020, an estimated $801K.
Genesee Capital Advisors first reported a position in PetMed Express in Q1 2020 and held it in 2 quarters.
Genesee Capital Advisors's PetMed Express position peaked at $801K in Q2 2020.
201 funds tracked by Wall St. Rank held PetMed Express as of Q3 2020.

Based on Genesee Capital Advisors's 13F filing for Q3 2020, filed 29 Oct 2020.